Evolus Reports Below-Expectation Q2 2025 Earnings Amid Declining U.S. Aesthetic Toxin Market

Evolus (NASDAQ:EOLS) reported second-quarter earnings below expectations, driven by a slowdown in the U.S. aesthetic toxin market and reduced demand for its product Jeuveau. The company noted that procedural volumes decelerated further during Q2 2025 after a slow start to the year.

By Motley Fool Transcribing, The Motley Fool May 4, 2026 35 min read · Yahoo Finance · May 4, 2026, 20:34 UTC

Topics: aesthetic_toxins consumer_sentiment market_share

Read the full article at Yahoo Finance

More World news

Micron Shares Decline Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 15:44 UTC
Wirex Launches Navoka AI Agent with Dedicated Bank Account and Card PR Newswire · November 12, 2026, 15:44 UTC
Mobility Global Shares Rise 12% Following Q3 Earnings Beat and Improved EBITDA Outlook Seeking Alpha · November 12, 2026, 15:44 UTC
Lucid Diagnostics Reports Q3 2026 Results Amid Transition to Medicare Reimbursement Motley Fool · November 12, 2026, 15:39 UTC
National Vision Reports Q3 2026 Revenue Growth Driven by Higher Average Ticket Motley Fool · November 12, 2026, 15:40 UTC
Okeanis Eco Tankers Reports Record Q3 2026 Results Driven by High Freight Rates Motley Fool · November 12, 2026, 15:41 UTC
Nvidia Shares Plunge Following Resignation of CEO Jensen Huang Motley Fool · November 12, 2026, 15:35 UTC
Jensen Huang Resigns as Nvidia CEO; Colette Kress Appointed Interim CEO TechCrunch · November 12, 2026, 15:37 UTC
Merck KGaA Raises 2026 Outlook Amid Pending Bio-Techne Acquisition Seeking Alpha · November 12, 2026, 15:31 UTC
Chinese AI Firms Seek Alternative Access to Nvidia Chips Amid Potential US Export Restrictions Seeking Alpha · November 12, 2026, 15:32 UTC